Aspire Biopharma Holdings (ASBP) Current Taxes (2022 - 2023)
Aspire Biopharma Holdings' (ASBP) quarterly Current Taxes came in at $152689.0 in Q1 2023, up 367.1% year-over-year from $32689.0 in Q1 2022, and up 24.45% quarter-over-quarter from $122689.0 in Q4 2022.
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) Current Taxes (2022 - 2023) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Current Taxes for 2 consecutive years, with $152689.0 the latest figure, recorded in Q1 2023.
- On a quarterly basis, Current Taxes rose 367.1% year-over-year to $152689.0 in Q1 2023; TTM through Mar 2023 was $152689.0, a 367.1% increase from a year earlier, with the FY2022 full-year figure at $122689.0, changed N/A from the prior year.
- Current Taxes was $152689.0 for Q1 2023 at Aspire Biopharma Holdings, up from $122689.0 in the prior quarter.
- Over five years, Current Taxes peaked at $152689.0 in Q1 2023 and troughed at $32689.0 in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | - |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 49.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 86.90 Mn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 74.18 Mn |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 152,689.00 |
| Dec 31, 2022 | 122,689.00 |
| Sep 30, 2022 | 92,689.00 |
| Jun 30, 2022 | 62,689.00 |
| Mar 31, 2022 | 32,689.00 |